Tyme Technologies Announces Launch of a Pancreatic Research Program with the Mayo Clinic Led by Dr. Martin Fernandez-Zapico

NEW YORK, Dec. 13, 2016, TYMI, (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (“Tyme” or “the Company”) (OTCQB:TYMI), a clinical-theatre pharmaceutical company focused on developing very much targeted cancer therapeutics for a uncontracted range of oncology indications, today announced the hurl of a Pancreatic Research Program with the Mayo Clinic led by Dr. Martin Fernandez-Zapico.

Dr. Martin E. Fernandez-Zapico, Associate Professor of Medicine and Pharmacology at the Mayo Clinic, is one international expert in the field of pancreatic cancer, a malady predicted to be the second leading cause of cancer in 2030. Dr. Fernandez-Zapico’s programs are affiliated with the Mayo Clinic Cancer Center, Department of Oncology, Division of Gastroenterology and Hepatology, and the Center during Cell Signaling in Gastroenterology. His study is supported by the National Institutes of Health (NIH), the NIH-funded Mayo Clinic Pancreatic Cancer Specialized Program of Research Excellence (SPORE), the NIH-funded Mayo Clinic Center because of Cell Signaling in Gastroenterology, and the Leukemia and Lymphoma Foundation. His be has been seminal for the reason of mechanisms driving this malignancy and serves during the time that a foundation for multiple National Cancer Institute sponsored clinical trials.

“Tyme is extremely pleased to exist working with Dr. Fernandez-Zapico of the Mayo Clinic in every effort to potentially discover the coming time cure of pancreatic cancer. I rely upon the pancreatic research experiments planned through Dr. Fernandez-Zapico, using our see preprinter discoveries and supported by Tyme, could persuade to significant progress in battling this devastating con~ation of cancer. We look forward to continuing our clinical progression in a continuously ascending gradation program in pancreatic and other cancers, based up~ collaborations with Mayo and other most important institutions,” said Dr. Del Priore, Chief Medical Officer of Tyme.

About Tyme

Our inquiry and development efforts are based in successi~ patented technologies and our patent unsettled proprietary platform technology, for which we retain global IP and commercial rights. Our have the ~ of program is SM-88, a see preprinter combination drug product. We believe SM-88 is a foremost-in-class oncology therapy that increases the prerogative of the body’s innate defenses to make useful oxidative stress to kill cancer cells. SM-88 is designed to enter only living cancer cells without toxic goods and without involving healthy body accumulation. We believe that SM-88’s therapeutic potential is based on its facility to increase the availability of bountiful radicals and promote their entry into cancer cells through stripping the cancer cells of their ordinary barriers to these toxic electrons. SM-88 is a conspiracy of a proprietary novel molecule by three currently-marketed drugs that are in general considered safe for their already approved indications, what one. are in areas other than cancer treatment.

Forward-Looking Statements

In addition to historical advice, this press release contains forward-looking statements inside of the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such brazen-faced-looking statements may include projections respecting Tyme’s future performance, and readers be possible to identify forward-looking statements by sentences or passages involving the employment of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “possible,” “predicts,” “projects,” “should,” “would” and uniform expressions intended to identify forward-looking statements. The at the fore part-looking statements contained in this clasp release are based on management’s current expectations, that are subject to uncertainty, risks and changes in pecuniary standing that are difficult to predict and crowd of which are outside of Tyme’s mastery. Forward-looking statements within this crowd release include, without limitation, statements respecting our drug development strategies, the curative mechanisms of our drug candidates and our completed and planned clinical trials. These statements imply known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, acting or achievements to be materially different from any historical results and time to come results, performances or achievements expressed or implied through the forward-looking statements. These risks and uncertainties hold, but are not limited to, the factors described in the part captioned “Risk Factors” of Tyme’s Annual Report steady Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).


Lisa Wilson
In-Site Communications, Inc.
T: (212) 452-2793
E: lwilson@insitecony.com

Lexapro could perchance be well tolerated by the manhood of folks with 90 per cent of the negative goods disappearing in the initial few weeks.

Recent Comments